A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Clinical trial NCT05703516 · RECRUITING

Trial details

NCT number: NCT05703516
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Study type: OBSERVATIONAL

Non-Small-Cell Lung Carcinoma

Start date: 2023-06-12
Primary completion: 2026-10-31
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.